Healthcare provider profile · identity verified

Colleen Smith, MD

Family Practice · PATASKALA, OH · NPI 1255330965

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	266	82
Lisinopril	Lisinopril	265	74
Amlodipine Besylate	Amlodipine Besylate	155	46
Omeprazole	Omeprazole	140	36
Losartan Potassium	Losartan Potassium	126	38
Gabapentin	Gabapentin	125	35
Levothyroxine Sodium	Levothyroxine Sodium	120	27
Rosuvastatin Calcium	Rosuvastatin Calcium	117	34
Metformin Hcl	Metformin Hcl	110	32
Potassium Chloride	Potassium Chloride	100	25
Pantoprazole Sodium	Pantoprazole Sodium	96	28
Simvastatin	Simvastatin	91	21
Pravastatin Sodium	Pravastatin Sodium	87	22
Hydrochlorothiazide	Hydrochlorothiazide	75	21
Metoprolol Succinate	Metoprolol Succinate	69	21
Alendronate Sodium	Alendronate Sodium	59	17
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	59	14
Bupropion Xl	Bupropion Hcl	55	15
Furosemide	Furosemide	55	17
Alprazolam	Alprazolam	54	suppressed
Citalopram Hbr	Citalopram Hydrobromide	50	14
Trazodone Hcl	Trazodone Hcl	48	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	46	13
Glimepiride	Glimepiride	44	14
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	44	suppressed
Prednisone	Prednisone	44	37
Albuterol Sulfate Hfa	Albuterol Sulfate	43	25
Carvedilol	Carvedilol	41	suppressed
Ozempic	Semaglutide	40	suppressed
Tizanidine Hcl	Tizanidine Hcl	39	18
Synthroid	Levothyroxine Sodium	38	suppressed
Glipizide Er	Glipizide	37	11
Metformin Hcl Er	Metformin Hcl	37	13
Metoprolol Tartrate	Metoprolol Tartrate	36	13
Escitalopram Oxalate	Escitalopram Oxalate	35	11
Montelukast Sodium	Montelukast Sodium	35	suppressed
Meloxicam	Meloxicam	34	suppressed
Tramadol Hcl	Tramadol Hcl	33	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	32	suppressed
Atenolol	Atenolol	31	suppressed
Lorazepam	Lorazepam	28	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	28	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	28	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	27	suppressed
Sertraline Hcl	Sertraline Hcl	27	13
Warfarin Sodium	Warfarin Sodium	27	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	27	suppressed
Azelastine Hcl	Azelastine Hcl	26	11
Buspirone Hcl	Buspirone Hcl	26	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	26	21
Fluoxetine Hcl	Fluoxetine Hcl	25	suppressed
Fluticasone Propionate	Fluticasone Propionate	24	14
Mounjaro	Tirzepatide	24	suppressed
Duloxetine Hcl	Duloxetine Hcl	23	suppressed
Famotidine	Famotidine	23	suppressed
Glipizide	Glipizide	22	suppressed
Ezetimibe	Ezetimibe	21	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	19	suppressed
Jardiance	Empagliflozin	19	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	16
Nadolol	Nadolol	17	suppressed
Celecoxib	Celecoxib	16	suppressed
Clopidogrel	Clopidogrel Bisulfate	16	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	16	suppressed
Ropinirole Hcl	Ropinirole Hcl	16	suppressed
Eliquis	Apixaban	15	suppressed
Januvia	Sitagliptin Phosphate	15	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Levalbuterol Tartrate Hfa	Levalbuterol Tartrate	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	13	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	13	suppressed
Naproxen	Naproxen	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Klor-Con M10	Potassium Chloride	12	suppressed
Nyamyc	Nystatin	12	suppressed
Allopurinol	Allopurinol	11	suppressed
Cephalexin	Cephalexin	11	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	11	suppressed
Linzess	Linaclotide	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error